Program
Ramucirumab
Also written as “IMC-1121B (ramucirumab)”, “Ramucirumab (IMC-1121B)” and “IMC-1121B”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Breast Neoplasms, led by 6 companies.
Drug pageRamucirumab: every studyMany companies study it; this page follows only the 58 they lead. All 109 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 533 open or running | phase 3since Jun 20, 2008 | Aug 13, 2007 | May 2027phase 2 · NCT05999994 |
| Arog Pharmaceuticalsits history only | 10 open or running | phase 1since Jun 14, 2017 | Jun 14, 2017 | none ahead |
| AstraZenecaits history only | 11 open or running | phase 2since May 5, 2025 | May 5, 2025 | Feb 23, 2029phase 2 · NCT06996782 |
| Innovent Biologicsits history only | 10 open or running | phase 3since Dec 3, 2020 | Dec 3, 2020 | none ahead |
| Merckits history only | 11 open or running | phase 2since May 31, 2024 | May 31, 2024 | May 9, 2028phase 2 · NCT06445972 |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 1since Mar 24, 2023 | Mar 24, 2023 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 38 studies since Aug 13, 2007.
- May 1, 2015Phase 3 study in Carcinoma, HepatocellularNCT02435433 · 399 enrolled · United States, Australia, Austria and more
- May 11, 2015Phase 1 study in Carcinoma, Non-Small-Cell LungNCT02443324 · 175 enrolled · United States, France, Germany and more
- May 12, 2015Phase 2 study in Stomach NeoplasmsNCT02443883 · 164 enrolled · United States, Argentina, Australia and more
- Jul 31, 2015Phase 2 study in Stomach NeoplasmsNCT02514551 · 245 enrolled · United States, Belgium, Canada and more
- Aug 31, 2015Phase 2 study in Metastatic Gastric AdenocarcinomaNCT02539225 · 191 enrolled · Japan, Korea, Republic of, Taiwan
- Sep 25, 2015Phase 1 study in NeoplasmsNCT02564198 · 29 enrolled · United States
- Mar 14, 2016Phase 2 study in Biliary Tract NeoplasmsNCT02711553 · 309 enrolled · United States, Argentina, Australia and more
- May 31, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungNCT02789345 · 29 enrolled · United States, France, Korea, Republic of and more
- Jul 11, 2016Phase 2 study in Carcinoma, Non-Small-Cell LungNCT02831491
- Sep 8, 2016Phase 3 study in Gastroesophageal Junction AdenocarcinomaNCT02898077 · 440 enrolled · China, Malaysia, Philippines and more
- Oct 29, 20192 phase 2 studiesNCT04145700, NCT04145349
- Jul 30, 2020Phase 1 study in HealthyNCT04495478 · 50 enrolled · United States
- Sep 16, 2020Phase 1 study in Advanced Solid TumorNCT04557384 · 3 enrolled · United States, Japan
- Aug 14, 2023Phase 2 study in NeoplasmsNCT05999994 · 105 planned · United States, Australia, Belgium and more
Ahead
- May 2027Primary completion: phase 2 study in NeoplasmsNCT05999994
TargetBeta
“A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity”NCIt, by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 53 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | May 2027 | 105 |
| NCT04557384Advanced Solid Tumor · United States, Japan | 1 | Terminated | May 25, 2021 | 3 |
| NCT04495478Healthy · United States | 1 | Completed | May 9, 2021 | 50 |
| NCT04145700Sarcoma, Synovial · United States, Australia, Belgium and more | 2 | Terminated | Feb 23, 2023 | 23 |
| NCT04145349Desmoplastic Small Round Cell Tumor · United States, Australia, Germany and more | 2 | Completed | Jun 14, 2024 | 30 |
| NCT02898077Gastroesophageal Junction Adenocarcinoma · China, Malaysia, Philippines and more | 3 | Completed | Jun 30, 2020 | 440 |
| NCT02831491Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Jul 2017 | 0 |
| NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more | 1 | Completed | Oct 19, 2017 | 29 |
| NCT02711553Biliary Tract Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Feb 16, 2018 | 309 |
| NCT02564198Neoplasms · United States | 1 | Completed | Jul 16, 2019 | 29 |
| NCT02539225Metastatic Gastric Adenocarcinoma · Japan, Korea, Republic of, Taiwan | 2 | Completed | Oct 25, 2017 | 191 |
| NCT02514551Stomach Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Oct 27, 2017 | 245 |
| NCT02443883Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Nov 18, 2016 | 164 |
| NCT02443324Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 1 | Completed | Aug 31, 2018 | 175 |
| NCT02435433Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Mar 15, 2018 | 399 |
| NCT02426125Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 3 | Completed | Apr 21, 2017 | 530 |
| NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 3 | Active, not recruiting | Jan 23, 2019 | 545 |
| NCT02314117Metastatic Gastric Adenocarcinoma · United States, Argentina, Belgium and more | 3 | Completed | Jan 17, 2017 | 645 |
| NCT02082210Liver Neoplasms · United States | 2 | Completed | Dec 5, 2017 | 97 |
| NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain | 1 | Completed | May 2, 2018 | 142 |
| NCT02069041Carcinoma, Hepatocellular · Taiwan | 1 | Completed | Sep 2016 | 8 |
| NCT01983878Stomach Neoplasms · Japan | 2 | Completed | Jan 2015 | 36 |
| NCT01703091Non-small Cell Lung Cancer Metastatic · Japan | 2 | Completed | Dec 2014 | 197 |
| NCT01682135Solid Tumor · China | 1 | Completed | Mar 2015 | 28 |
| NCT01634555Solid Tumors · United States | 2 | Completed | Aug 2013 | 29 |
| NCT01567163Malignant Solid Tumor · United States | 2 | Completed | Dec 2012 | 22 |
| NCT01515306Malignant Solid Tumor · United States | 2 | Completed | Mar 20, 2013 | 48 |
| NCT01427933Breast Neoplasms · United States | 2 | Completed | Sep 2013 | 141 |
| NCT01286818Colorectal Neoplasms · Japan | 1 | Completed | Feb 2012 | 6 |
| NCT01282463Urethral Neoplasms · United States, Canada | 2 | Completed | Feb 2015 | 148 |
| NCT01256567Breast Neoplasms · Japan | 1 | Completed | Nov 2012 | 7 |
| NCT01253525Adenocarcinoma · Japan | 1 | Completed | Oct 2011 | 6 |
| NCT01246960Stomach Neoplasms · United States | 2 | Completed | Sep 2013 | 168 |
| NCT01234402Breast Neoplasms · United States, Canada | 2 | Completed | Oct 2013 | 153 |
| NCT01183780Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jul 17, 2014 | 1,072 |
| NCT01170663Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jul 2013 | 665 |
| NCT01168973Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Completed | Dec 2013 | 1,253 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Jan 2014 | 280 |
| NCT01140347Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Mar 2014 | 565 |
| NCT01111604Colonic Neoplasms · United States, Canada | 2 | Completed | Dec 2013 | 158 |
| NCT01017731Neoplasms · United States | 2 | Completed | Apr 2010 | 68 |
| NCT01005355Advanced Solid Tumors · Japan | 1 | Completed | Feb 2011 | 15 |
| NCT00917384Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jul 2012 | 355 |
| NCT00862784Colorectal Neoplasms · Canada, Spain | 2 | Completed | Apr 2011 | 48 |
| NCT00793975Neoplasms · United States | 1 | Completed | Jun 2009 | 37 |
| NCT00786383Neoplasms · United States | 1 | Completed | Jan 2009 | 25 |
| NCT00735696Carcinoma, Non-Small-Cell Lung · United States, United Kingdom | 2 | Completed | Oct 2011 | 41 |
| NCT00721162Ovarian Neoplasms · United States, United Kingdom | 2 | Completed | May 2012 | 60 |
| NCT00703326Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Mar 31, 2013 | 1,144 |
| NCT00683475Prostatic Neoplasms · United States | 2 | Completed | Sep 2011 | 138 |
| NCT00627042Carcinoma, Hepatocellular · United States | 2 | Completed | May 2011 | 42 |
| NCT00533702Melanoma · United States | 2 | Completed | May 2011 | 106 |
| NCT00515697Carcinoma, Renal Cell · United States | 2 | Completed | May 2011 | 39 |
How it is read
Names in the registry
- “Ramucirumab”, 36 entries
- “IMC-1121B (ramucirumab)”, 4 entries
- “Ramucirumab (IMC-1121B)”, 4 entries
- “IMC-1121B”, 4 entries
- “ramucirumab (IMC-1121B)”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Stomach Neoplasms, 7 studies
- Neoplasms, 5 studies
- Carcinoma, Hepatocellular, 4 studies
- Breast Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.